Disomotide

DB17469Investigational

Disomotide is a synthetic peptide cancer vaccine.

Mechanism
Curator reviewed
Also known as
Gp-100:209-217(210m) peptide · Gp100:209-217(210m) peptide · L-valine, l-isoleucyl-l-methionyl-l-.alpha.-aspartyl-l-glutaminyl-l-valyl-l-prolyl-l-phenylalanyl-l-seryl-
Code names
MPS-22

Resolves to

Compound
UNII8028PPX4PMCAS181477-43-0
Targets
P40967PMEL

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Disomotide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In